Document Type
Patent
Publication Date
October 2009
Patent Number
7601696
Abstract
Oct-1 is shown to be an oncoprotein because of its known role as an activator of the histone H2B gene and the importance of this gene during DNA synthesis. To determine the role of Oct-1 as an oncoprotein, the cell line 5637 (ATCC HTB9) was transfected with the vector pcDNA3 containing full length, antisense Oct-1 cDNA. This cell line is Rb-defective and has been shown to have increased Oct-1 binding activity as compared to Rb reconstituted clones. After transfection, Oct-1 antisense clones were grown and assayed for the loss of oncogenic characteristics as compared to control transformants.
Application Number
10/711,101
Recommended Citation
Blanck, George; Palubin, Kimberly; and Osborne, Aaron, "Oct-1 as an oncoprotein and use of nucleic acid inhibitors of Oct-1 for cancer treatment" (2009). USF Patents. 570.
https://digitalcommons.usf.edu/usf_patents/570
Assignees
University of South Florida
Filing Date
08/23/2004
Primary/U.S. Class
514/44
